Compare United States Copper Index Fund (CPER) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Copper Index Fund vs Recursion Pharmaceuticals Inc — how do they compare? United States Copper Index Fund trades at $40.29 (market cap $708.28M), while Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3× United States Copper Index Fund's market cap, and United States Copper Index Fund is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| CPER | RXRX | |
|---|---|---|
Market Cap | $708.28M | $2.14B |
Volume | 339,046 | 30,789,535 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $6.79 |
52-Week Low | $30.27 | $2.84 |
Typical Hold Time | 48 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish momentum in moving averages but neutral oscillators, with key support at $39 and resistance at $40. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper prices have shown volatility with recent declines.
The outlook for CPER is mixed, with positive copper demand fundamentals balanced by near-term price volatility. Investment opportunities center on exposure to copper's role in AI and electrification trends, while risks include commodity price swings and potential supply chain disruptions. Wall Street sentiment appears cautiously optimistic given copper's strategic importance.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About United States Copper Index Fund
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
